Skip to main content
AmigoFish

STIFEL 2026: With expertise in the next generation of GPCR development, Septerna will have initial in human data on its oral PTH19 agonist for hypoparathyroidism in Q1

From BiotechTV - News · · 9 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Co-Founder & CEO Jeff Finer walks us through the company's GPCR discovery platform, and discusses, this lead program, a new target (TSHR) they just named in Grave's disease and thyroid eye disease, and the company's work in obeisty with partner Novo Nordisk.

Back to BiotechTV - News · Report a problem